Page 63 - Read Online

Page 38 of 38 J Cancer Metastasis Treat 2020;6:5 I http://dx.doi.org/10.20517/2394-4722.2020.13

Results: After three months of well tolerated treatment, we observed a partial response in 77.8% (7/9
patients), stable disease in 11.1% (1/9), and 11.1% (1/9) presented with progressive disease. Among the
patients assigned to the standard diet (control group), the partial response was 25% (2/8 patients), stable
disease was 25% (2/8), and progressive disease was 50% (4/8 patients). The patients assigned to the KD
group presented with: reduced frequency of seizures, a slight increase in lean muscle mass, reduced serum
lipid levels, and decreased low-density lipoprotein cholesterol (LDL-C) levels.

Conclusion: These results are encouraging and suggest that KD associated with intranasal POH may
represent a viable option as an adjunct therapy for recurrent GBM.